JonesTrading Initiates Coverage of Evaxion A/S with Buy Rating

Investment firm JonesTrading has commenced coverage on shares of Evaxion A/S (NASDAQ: EVAX), issuing a buy rating along with a price target of $10.00. This announcement came in a report published on March 5, 2024, reflecting a positive outlook for the biotechnology company based in Copenhagen, Denmark.

Several other research analysts have recently evaluated Evaxion’s stock, contributing to a diverse range of opinions. Lake Street Capital reduced its price target from $11.00 to $9.00 on the same day, while maintaining a buy rating. Meanwhile, Maxim Group, which started its coverage on February 19, 2024, set a price objective of $10.00 with a buy recommendation.

On that day, HC Wainwright reiterated its buy rating, setting a more ambitious price target of $16.00. Conversely, Weiss Ratings assigned a sell rating with a grade of D- in its latest evaluation. Overall, five analysts have rated the stock as a buy, while one has issued a sell rating. Currently, the average rating stands at “Moderate Buy,” with an average price target of $11.00, according to MarketBeat.com.

Evaxion A/S recently reported its quarterly earnings, highlighting an earnings per share (EPS) of $0.30. Analysts expect the company to post an EPS of -0.15 for the current fiscal year. The stock has experienced an increase of 8.0% in recent trading, reflecting growing investor interest.

Institutional investors have also been active in modifying their stakes in Evaxion. Notably, Wesbanco Bank Inc. acquired a new stake valued at $48,000 during the fourth quarter. Additionally, Northwestern Mutual Wealth Management Co. invested $38,000, and SmartHarvest Portfolios LLC secured a position worth $72,000. Collectively, institutional investors now hold approximately 11.04% of the company’s stock.

Evaxion A/S specializes in developing immunotherapies and vaccines, leveraging its proprietary AI-based computational immunology platform. This innovative approach combines machine learning and deep learning algorithms to identify and optimize antigen targets for therapeutic cancer vaccines and preventive vaccines against infectious diseases. By analyzing comprehensive datasets of genomic, proteomic, and immunological information, the platform aims to predict immune-stimulating epitopes effectively.

As the company continues to advance its clinical-stage projects, the latest ratings and institutional investments signify a critical period for Evaxion A/S.